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Abstract
Dendritic cells (DCs) are the quintessential antigen-presenting cells of the human immune system and play a prime role in
coordinating innate and adaptive immune responses, explaining the strong and still growing interest in their application for
cancer immunotherapy. Much current research in the field of DC-based immunotherapy focuses on optimizing the culture
conditions for in vitro DC generation in order to assure that DCs with the best possible immunogenic qualities are being
used for immunotherapy. In this context, monocyte-derived DCs that are alternatively induced by interleukin-15 (IL-15 DCs)
have attracted recent attention due to their superior immunostimulatory characteristics. In this study, we show that IL-15
DCs, in addition to potent tumor antigen-presenting function, possess tumoricidal potential and thus qualify for the
designation of killer DCs. Notwithstanding marked expression of the natural killer (NK) cell marker CD56 on a subset of IL-15
DCs, we found no evidence of a further phenotypic overlap between IL-15 DCs and NK cells. Allostimulation and antigen
presentation assays confirmed that IL-15 DCs should be regarded as bona fide myeloid DCs not only from the phenotypic
but also from the functional point of view. Concerning their cytotoxic activity, we demonstrate that IL-15 DCs are able to
induce apoptotic cell death of the human K562 tumor cell line, while sparing tumor antigen-specific T cells. The cytotoxicity
of IL-15 DCs is predominantly mediated by granzyme B and, to a small extent, by tumor necrosis factor-a (TNF-a)-related
apoptosis-inducing ligand (TRAIL) but is independent of perforin, Fas ligand and TNF-a. In conclusion, our data provide
evidence of a previously unappreciated role for IL-15 in the differentiation of human monocytes towards killer DCs. The
observation that IL-15 DCs have killer DC capacity lends further support to their implementation in DC-based
immunotherapy protocols.
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Introduction
Over the past years, the phenotypic and functional boundaries
distinguishing the main cell subsets of the human immune system
have become increasingly blurred. While it has already been well
established that T cells may share some phenotypic and functional
features with natural killer (NK) cells [1], more recent evidence
also points to the existence of such overlap between NK cells and
dendritic cells (DCs) [2]. NK cells have been shown capable of
antigen presentation, a classical function of DCs [3]. In mice,
specialized NK cell subsets, collectively designated as ‘natural killer
dendritic cells’ (NKDCs), have been identified that display a hybrid
NK cell/DC phenotype and combine functional properties of NK
cells (cytotoxicity) and DCs (antigen presentation) [4–9]. Con-
versely, evidence from both rodent and human studies is emerging
that DCs may exhibit NK-like activity and play a direct role in
innate immunity as killer cells; in the literature, these cells are
designated as ‘killer DCs’ [10–13]. Such killer DCs that can
combine both tumor antigen presentation function with direct
tumoricidal activity are garnering increasing attention as potential
new, multifunctional tools for cancer immunotherapy [10–12,14].
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e51851
Hitherto, monocyte-derived DCs represent the DC type most
widely used in human immunotherapy trial protocols [15,16].
They are classically obtained through in vitro differentiation of
peripheral blood monocytes in the presence of granulocyte
macrophage colony-stimulating factor (GM-CSF) and interleukin
(IL)-4 [17], followed by induction of DC maturation using a pro-
inflammatory cytokine cocktail composed of tumor necrosis factor
(TNF)-a, IL-1b, IL-6 and prostaglandin E2 (PGE2) [18]. Over the
years, it has become apparent that these ‘‘gold-standard’’ DCs,
commonly referred to as ‘IL-4 DCs’, are suboptimal in terms of
antigen presentation function and T cell stimulatory capacity [17].
This explains the impetus behind the many efforts that are
currently being made to optimize the culture conditions for ex vivo
monocyte-derived DC generation [19,20].
Within this context, we and others have shown that the
immunostimulatory properties of monocyte-derived DCs can be
significantly enhanced by replacing IL-4 with IL-15 for DC
differentiation and by using Toll-like receptor (TLR) stimuli to
trigger DC maturation [17,21–23]. In addition, we have found
that these so-called ‘IL-15 DCs’ display a rather unconventional
DC phenotype, with a subset of these cells being positive for the
cell surface marker CD56 [17]. Since CD56 is the archetypal
phenotypic marker of NK cells, we here aimed to investigate
whether IL-15 DCs also bear functional resemblance with NK
cells in terms of cytotoxic activity. In this study, IL-15 DCs are
shown to possess potent tumor antigen presentation function in
combination with lytic potential against the classical NK cell target
cell line K562, thus confirming the hypothesis that IL-15 DCs
qualify for the designation of killer DCs.
Methods
Ethics statement
This study was approved by the Ethics Committee of the
University of Antwerp (Antwerp, Belgium) under the reference
number 11/47/366. All experiments were performed using blood
samples from anonymous volunteer donors, provided through the
Antwerp Blood Transfusion Center of the Red Cross (Edegem,
Belgium).
Human cell lines
The human myeloid leukemia cell lines K562 and U937 were
obtained from American Type Culture Collection (Rockville, MD,
USA) and maintained in Iscove’s modified Dulbecco’s medium
(IMDM; Invitrogen, Merelbeke, Belgium) supplemented with 10%
fetal bovine serum (FBS; Invitrogen). The human cytotoxic T
lymphocyte (CTL) clone specific for the HLA-A*0201-restricted
epitope 126–134 of the Wilms’ tumor 1 protein (WT1) [24] was
kindly provided by Dr C. Bonini (San Raffaele Scientific Institute,
Milan, Italy) and maintained in IMDM/10% FBS and 60 IU/mL
IL-2 (Immunotools, Friesoythe, Germany).
DC culture
Mature IL-15 DCs were generated according to our previously
described protocol [17]. Briefly, peripheral blood mononuclear
cells (PBMCs) were prepared from buffy coats by standard Ficoll
density gradient centrifugation (Ficoll-PaqueTM PLUS; GE
Healthcare, Diegem, Belgium). CD14+ monocytes were purified
using a positive immunomagnetic cell selection kit (Miltenyi,
Amsterdam, The Netherlands) and seeded into 6-well culture
plates (Corning Life Sciences, Schiphol-Rijk, The Netherlands) at
a density of 1–1.26106/mL in DC differentiation medium
containing Roswell Park Memorial Institute medium (RPMI-
1640; Invitrogen), 2.5% heat-inactivated human AB serum
(Invitrogen), 800 IU/mL GM-CSF (Invitrogen) and 200 ng/mL
IL-15 (Immunotools). After 24–36 hr of in vitro culture, CD56+ and
CD562 IL-15 DC populations were separated using anti-CD56
magnetic microbeads according to the manufacturer’’s instructions
(Miltenyi). Both fractions were resuspended in DC differentiation
medium and cultured for an additional 16–20 hr in the presence
of a DC maturation cocktail containing 3 mg/mL of the TLR7/8
ligand R-848 (Enzo Life Sciences, Antwerp, Belgium), 2.5 ng/mL
TNF-a (Gentaur, Brussels, Belgium), 5000 IU/mL interferon-c
(IFN-c; Immunotools) and 1 mg/mL PGE2 (Pfizer, Puurs,
Belgium). In some experiments, IL-15 DC function was compared
to that of conventional 7-day GM-CSF/IL-4 monocyte-derived
DCs (IL-4 DCs), which were generated as described previously
[17].
Flow cytometric immunophenotyping
Purity of IL-15 DC cultures was checked on a routine basis by
multiparameter flow cytometry using a combination of FITC-, PE-
, PB-/V450- and APC-conjugated monoclonal antibodies (mAbs)
specific for CD3, CD7, CD11c, CD19 and CD56. All mAbs were
from Becton Dickinson (BD; Erembodegem, Belgium) unless
specified otherwise. Cell surface staining of mature IL-15 DCs was
performed using FITC-, PE-, PB-/V450-, or APC-conjugated
mAbs against various NK cell markers (CD7, CD16, CD56,
CD69, NKG2D [Miltenyi], NKp46), NKDC-associated surface
antigens (CD11c, B220 [eBioscience, Halle-Zoersel, Belgium],
NKR-P1A/CD161 [Miltenyi]) and monocyte/DC markers
(BDCA-1/CD1c [Miltenyi], CD14, CD40, CD80, CD83 [In-
vitrogen], CD86, CD209/DC-SIGN, CCR7 [R&D Systems,
Minneapolis, MN, USA], HLA-DR). For detection of mem-
brane-bound cytolytic effector molecules, DCs were stained with
PE-labeled mAbs against TNF-a, Fas ligand/CD178 (eBioscience)
and TNF-a-related apoptosis-inducing ligand (TRAIL). Dead cells
were excluded by 7-amino actinomycin D (7-AAD; 5 mL/sample;
BD) staining 10 min prior to acquisition on a FACSAria II (BD)
flow cytometer. In each experiment, isotype-matched control
mAbs were included to determine non-specific background
staining. Results were expressed as delta mean fluorescence
intensity (DMFI) (calculated by subtracting MFI values of isotype
controls from sample MFI values) and as percentages of marker-
positive cells (determined by Overton subtraction of isotype
control histograms from sample histograms).
CD56 expression kinetics
In a separate experiment designed to study the kinetics of CD56
expression during IL-15 DC differentiation, ultra-purified FACS-
sorted monocytes were used as precursor cells for IL-15 DC
differentiation. For this specific experiment, CD14 magnetic bead-
selected monocytes were stained with CD14-PerCP-Cy5.5/CD16-
V500 (both from BD) and then flow-sorted using an Influx
cytometer (BD). Sorting gates were set conservatively on
CD14++CD162 cells to ensure high-purity isolation (.99.9%) of
the ‘‘classical’’ monocyte subset. Sorted monocytes were then
subjected to IL-15 DC differentiation as described above. Flow
cytometric analysis of CD56 expression on IL-15 DCs was
performed at different time points following start of culture (4 hr,
16 hr, 24 hr, 40 hr, 48 hr, 64 hr, 72 hr, 96 hr and 7 days) by
double surface staining with CD11c-APC (BD) and CD56-PB
(BioLegend, San Diego, CA, USA). At each time point, samples
were stained in parallel with CD11c-APC (BD) and a PB-labeled
isotype-matched control mAb (mouse IgG2a, k; BioLegend) to
determine non-specific background labeling. Samples were
acquired on an Influx cytometer (BD).
Interleukin-15-Induced Killer Dendritic Cells
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Combined cell surface and intracellular staining
Brefeldin A (1 mL/106 cells; Invitrogen) was added to the DC
cultures 180 min prior to harvesting the cells. After harvest, cells
were surface-stained with CD11c-V450 and CD56-APC (both
from BD). The LIVE/DEADH fixable violet stain with 405 nm
excitation (1 mL/106 cells; Invitrogen) was concomitantly added to
allow discrimination between viable and non-viable cells. After
30 min incubation at room temperature, cells were treated
sequentially with FACS lysing solution and FACS permeabilizing
solution 2 (BD). Intracellular expression of cytolytic effector
molecules was assessed after 4–6 hr incubation at 4uC with one of
the following mAbs or their corresponding isotype controls:
perforin-FITC, granzyme B-PE or TRAIL-PE (all from BD).
Samples were acquired using a FACSAria II cytometer (BD).
Results were expressed as DMFI values, as specified above.
Granzyme B secretion
CD56+ and CD562 IL-15 DCs were harvested 16–20 hours
following addition of the maturation cocktail, washed, and
resuspended in IMDM/10% FBS at a density of 26106 viable
cells/mL. Cell-free culture supernatants were collected after
overnight incubation and cryopreserved at 220uC for later
analysis. Thawed supernatants were diluted 5-fold to allow
quantification of granzyme B using a commercially available
ELISA kit according to the manufacturer’s instructions (Diaclone,
Besanc¸on, France).
Allogeneic mixed lymphocyte reaction (allo-MLR)
To prepare the responder cells for the MLR, frozen CD14+
monocyte-depleted PBMCs of an allogeneic blood donor were
thawed and further depleted of NK cells and NKT cells using anti-
CD56 magnetic microbeads (Miltenyi). The resultant lymphocyte
fraction was then labeled with 5,6-carboxyfluorescein diacetate
succinimyl ester (CFSE; 5 mM; Invitrogen), and co-cultured with
mature CD56+ and CD562 IL-15 DCs in a 96-well round-bottom
plate (Corning) at a stimulator:responder ratio of 1:10. Unstimu-
lated CFSE-labeled cells served as negative control, while CFSE-
labeled responders cells stimulated by either IL-4 DCs or
a combination of phytohemagglutinin (PHA; 1 mg/mL; Sigma-
Aldrich, Bornem, Belgium) and IL-2 (20 IU/mL; Immunotools)
served as positive controls. After 5 days, cells were stained with
CD11c-V450, CD3-APC and CD4-APC-H7 (all from BD) and
analyzed using a FACSAria II cytometer (BD). T cell proliferation
was assessed by quantifying the percent of CFSE-diluted (CFSElow)
cells within the CD11c2CD3+CD4+ gate after background
subtraction.
Antigen presentation assay
To evaluate their capacity for tumor antigen processing and
presentation, IL-15 DCs were loaded by electroporation with in
vitro transcribed WT1-encoding RNA. WT1 RNA was produced
by eTheRNA (Prof K. Thielemans, Free University of Brussels,
Brussels, Belgium) starting from a T7 promotor-driven plasmid
containing the codon-optimized (GeneArt, Regensburg, Germany)
human WT1 gene, lacking its 59-,39-untranslated regions as well as
the aa292–348 nuclear localization sequence and flanked at its 59-
and 39-sides, respectively, by the signal sequence and the HLA
class II-targeting sequence of DC-lysosome-associated membrane
protein [20]. IL-15 DCs from HLA-A*0201+ individuals were
prepared and electroporated as previously described [17], with
minor modifications. Briefly, 56106 cells were transferred to a 4-
mm electroporation cuvette (Bio-Rad, Hercules, CA, USA) and
electrotransfected with 20 mg RNA by an exponential decay pulse
of 300 V/300 mF using the Gene Pulser Xcell device (Bio-Rad).
Four hours post-electroporation, cells were transferred to 96-well
round-bottom plates (Corning) and co-cultured in triplicate with
the WT1126–134-specific CTL clone at a DC-to-T cell ratio of 1:1.
The next day, supernatants were collected and analyzed for IFN-c
production by ELISA as per the manufacturer’s instructions
(Peprotech, Rocky Hill, NJ, USA). In parallel experiments, WT1
RNA-electroporated IL-15 DCs were co-cultured with the CTL
clone at a DC-to-T cell ratio of 40:1 in triplicate wells of anti-IFN-
c-antibody-coated 96-well PVDF-bottom ELISpot plates (Milli-
pore, Bedford, MA, USA). After overnight co-culture at 37uC,
plates were developed using a commercially available IFN-c
ELISpot kit (Diaclone). IFN-c spot-forming cells (SFCs) were
counted with a computerized ELISpot plate reader (Autoimmun
Diagnostika, Strassberg, Germany). In each assay, the following
controls were included to determine the levels of non-antigen-
specific IFN-c production: T cells cultured alone, DCs cultured
alone and T cells cultured with non-antigen-loaded DCs.
Cytotoxicity assays
A flow cytometry-based lysis assay [25] was used to determine
the cytotoxic activity of IL-15 DCs against the following potential
targets: the K562 human myeloid leukemia cell line (major
histocompatibility complex [MHC] class I-negative), the U937
human myeloid leukemia cell line (MHC class I-positive) and the
WT1126–134-specific CTL clone. Briefly, target cells were labeled
with the PKH67 green fluorescent cell linker (Sigma-Aldrich). DCs
were harvested following maturation, rigorously washed, and co-
cultured overnight with PKH67-labeled target cells in fresh
IMDM/10% FBS medium at different effector-to-target (E:T)
ratios (50:1, 25:1, 12:1, 6:1 and 1:1). Prior to flow cytometric
measurement, the cell surface was stained with CD11c-V450 (BD)
to allow further discrimination between effector cells
(PKH672CD11c+) and targets cells (PKH67+CD11c2). The cells
were then washed and resuspended in Annexin-V-binding buffer
(BD) containing Annexin-V-APC (1 mL/100 mL buffer; BD). After
15 min incubation at room temperature, samples were stained
with propidium iodide (PI; Sigma-Aldrich) and immediately
acquired on a Partec CyFlow ML (Partec, Mu¨nster, Germany)
or a FACSAria II (BD) multiparameter flow cytometer. PKH67-
labeled target cells cultured without DCs served as controls to
determine spontaneous cell death. Percentages of viable target cells
(i.e. percentages of PI2/Annexin-V2 cells within the PKH67+/
CD11c2 target cell gate) were used to quantify the cytotoxic
responses according to the following formula: % of specific lysis
= 100– [(% viable target cells in the presence of DCs/% viable
target cells without DCs)6100].
Cytotoxicity blocking studies
Cytotoxicity blocking experiments were performed as described
above, except that effector cells (CD56+ IL-15 DCs) were pre-
incubated at 37uC with either neutralizing TRAIL mAbs (40 mg/
106 cells; R&D Systems) or concanamycin A (200 nM/106 DCs;
Tocris Bioscience, Bristol, UK) before addition of PKH67-labeled
K562 target cells at a 50:1 E:T ratio. Control experiments were
run in parallel using TRAIL isotype control mAbs (mouse IgG1;
R&D Systems) or concanamycin A control medium, respectively.
Data mining and statistical analysis
Flow cytometry data were analyzed using FlowJo software (v9.3;
Treestar, Ashland, OR, USA). GraphPad Prism software (v5.0;
San Diego, CA, USA) was used for statistical analysis and
graphing. Statistical comparisons were performed using Wilcox-
on’s matched-pairs signed rank test or paired Student’s t-test,
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where appropriate. P-values ,0.05 were considered statistically
significant. All data were expressed as means 6 standard error of
the mean (SEM).
Results
IL-15 DCs are CD56+/2 myeloid DCs that are
phenotypically unrelated to NK cells
Exposure of human peripheral blood CD14+ monocytes to GM-
CSF and IL-15 resulted in their rapid differentiation into CD11c+
DCs with subset expression of CD56 (Figure 1A, left panel).
Acquisition of CD56 was also demonstrable on IL-15 DCs
differentiated from ultra-purified, FACS-sorted CD14+ mono-
cytes, with CD56 being detectable already within the first 24 hr of
culture. Maximal CD56 surface expression was observed between
24–48 hr after start of IL-15 DC culture, after which expression
gradually declined toward the non-specific background level at day
7 (Figure S1).
Further phenotypic analysis of the CD56+ IL-15 DC fraction
revealed that this subset displayed the characteristic forward
scatter (FSC)/sideward scatter (SSC) profile of DCs (data not
shown) and that it co-expressed CD11c and BDCA-1, indicating
a myeloid DC phenotype (Figure 1A, middle panel). In addition,
CD56+ IL-15 DCs were found to lack co-expression of CD7,
which confirmed that these cells are unrelated to NK cells
(Figure 1A, right panel) [26]. Natural cytotoxicity receptors
(NCRs), such as the NK cell-specific marker NKp46 [27], and
other typical NK cell-associated markers, such as CD16, CD69 or
NKG2D, were not expressed on the cell surface of CD56+ IL-15
DCs (Figure 1B, ‘NK panel’).
The co-expression of CD11c with the prototypical NK cell
marker CD56 led us to further investigate whether the phenotype
of CD56+ IL-15 DCs might correspond to that of the so-called
NKDCs in mice [5–7]. Notwithstanding expression of CD11c, we
were unable to classify CD56+ IL-15 DCs as their human
counterpart due to the lack of NKDC-associated surface hallmarks
such as NKR-P1A/CD161, which is the human homologue of
murine NK1.1 [28], and B220 (Figure 1B, ‘NKDC panel’).
After 2–3 days of culture, including a maturation step during
the final 16–20 hr, both CD56+ and CD562 IL-15 DC
populations developed a mature DC phenotype characterized by
a marked down-regulation of CD14, up-regulation of DC-SIGN,
high-level expression of co-stimulatory molecules (CD40, CD80
and CD86) and of HLA-DR as well as of the maturation markers
CD83 and CCR7 (Table 1 and Figure 1B, ‘DC panel’). Compared
to their CD562 counterparts, CD56+ IL-15 DCs showed more
prominent down-regulation of CD14 along with significantly
higher expression levels of CD40, CD80, CD86, CD83 and
CCR7, indicative of a more differentiated and/or activated DC
phenotype (Table 1).
IL-15 DCs possess allo-stimulatory capacity
Next, CD56+ and CD562 IL-15 DC subpopulations were
subjected to an allo-MLR in order to examine their ability to
stimulate allogeneic T cell proliferation, one of the defining
functional characteristics of DCs [29]. While NK cells were unable
to stimulate allogeneic T cell proliferation (data not shown), IL-15
DCs were found to possess potent allostimulatory capacity, as
determined by CFSE dilution analysis (Figure 2). There was no
statistically significant difference between the percent of CFSElow
CD4+ T cells in CD56+ as compared to CD562 IL-15 DC-
stimulated cultures (background-subtracted % CFSElow CD4+ T
cells following stimulation with CD56+ vs. CD562 DCs:
24.163.9% vs. 19.762.6%; P.0.05).
IL-15 DCs are functional DCs with potent tumor antigen-
presenting capacity
To determine their capacity for tumor antigen presentation, IL-
15 DCs were loaded by RNA electroporation with the WT1 tumor
antigen [30] and examined for their ability to trigger IFN-c
production by a WT1126–134-specific CTL clone. WT1 RNA-
electroporated IL-15 DCs elicited a marked increase in IFN-c
secretion, as determined by ELISA, indicating that RNA trans-
lation and processing for MHC class I presentation had occurred
in these cells. Production of IFN-c in response to non-antigen-
loaded IL-15 DCs was approximately 3.3-fold lower as compared
to WT1 RNA-electroporated IL-15 DCs, confirming the antigen
specificity of the responses observed (Figure 3A; WT1 RNA EP vs.
non/mock EP: P,0.001 and P=0.01 for CD56+ and CD562 IL-
15 DCs, respectively). WT1 RNA-electroporated CD56+ IL-15
DCs were significantly more efficient at antigen presentation than
their CD562 counterparts, as was demonstrated by their superior
capacity to stimulate the CTL clone to secrete IFN-c (Figure 3A,
WT1 RNA EP CD56+ vs. CD562 IL-15 DCs: P=0.003).
Results of the IFN-c ELISpot assay were similar to those
obtained by ELISA. As shown in Figure 3B, both CD56+ and
CD562 WT1 RNA-electroporated IL-15 DCs were able to induce
robust IFN-c ELISpot responses. Numbers of IFN-c SFCs/well in
non-antigen-stimulated cultures (i.e. CTL clone cultured with non-
antigen-loaded DCs) did not differ significantly between CD56+
and CD562 IL-15 DCs and were found to be consistently lower
than those in corresponding cultures stimulated with WT1 RNA-
electroporated IL-15 DCs (Figure 3B; WT1 RNA EP vs. non/
mock EP: P,0.001 for both CD56+ and CD562 IL-15 DCs).
Although WT1 RNA-electroporated CD562 IL-15 DCs induced
a potent IFN-c ELISpot response (SFCs/well: 141.463.3),
significantly higher numbers of IFN-c SFCs/well (184.468.0)
were observed whenWT1 RNA-electroporated CD56+ IL-15 DCs
were used as effectors (P,0.001), confirming the superiority of
CD56+ over CD562 IL-15 DCs in terms of antigen-presenting
capacity (Figure 3B).
IL-15 DCs are killer DCs capable of tumor lysis while
sparing antigen-specific T cells
The observation that a subset of IL-15 DCs expressed the
classical NK cell marker CD56 prompted us to examine whether
these DCs have cytolytic effector function. Therefore, both CD56+
and CD562 IL-15 DC fractions were co-cultured with the K562
tumor cell line and examined for lytic activity using a PI/Annexin-
V-based flow cytometric lysis assay. After 16–18 hr of co-culture,
CD56+ IL-15 DCs were found to have reduced K562 cell viability
by 22.761.0% at an E:T ratio of 50:1 (Figure 4). This decrease in
K562 cell viability was due to an increase in apoptotic cell death,
as indicated by the higher frequency of PI+Annexin-V+ K562
target cells after co-culture with CD56+ IL-15 DCs (Figure 4A). As
shown in Figure 4B, the cytotoxic action of CD56+ IL-15 DCs was
titratable and most apparent at high E:T ratios, where levels of
cytotoxicity between CD56+ and CD562 IL-15 DCs were found
to differ significantly (Figure 4B; P,0.001 and P=0.006 for E:T
ratios of 50:1 and 25:1, respectively). At these E:T ratios, lytic
activity of CD562 IL-15 DCs was markedly lower as compared to
that of CD56+ DCs, but still higher than that of conventional IL-4
DCs which failed to induce any significant cytotoxicity (Figure 4B).
We next sought to determine whether IL-15 DCs display any
non-specific cytotoxic activity against tumor antigen-specific T
cells, which would be unwanted in the context of immunotherapy.
To this end, mature CD56+ and CD562 IL-15 DCs derived from
HLA-A*0201+ donors were added to the WT1126–134-specific
Interleukin-15-Induced Killer Dendritic Cells
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CTL clone at a 50:1 E:T ratio. Residual cell viability was
determined after overnight incubation by PI/Annexin-V staining.
Figure 4C shows that there was no significant difference in T cell
clone viability regardless of the presence or absence of IL-15 DCs,
confirming that IL-15 DCs lack lytic activity against WT1-specific
T cells (Figure 4C; T cells vs. T cells + DCs: P.0.05 for both
CD56+ and CD562 IL-15 DCs).
Figure 1. Phenotypic characteristics of CD56+ IL-15 DCs. (A) CD14+ monocytes were cultured for 24–36 hr in the presence of GM-CSF and IL-
15 (IL-15 DCs) and analyzed by flow cytometry for expression of CD11c/CD56 (left). The percentage between parentheses indicates the mean (6 SEM)
percentage of CD56+ cells among the total IL-15 DC population (n=17). These CD56+ cells were then immunomagnetically separated, cultured for
another 16–20 hr in the presence of DC maturation cocktail and analyzed for co-expression of CD11c/BDCA-1 (middle) and CD56/CD7 (right).
Quadrant gates were set using corresponding isotype controls. (B) Matured CD56+ IL-15 DCs were further analyzed by flow cytometry for expression
of the indicated NK cell-associated (CD56, CD7, CD16, CD69, NKG2D, NKp46), NKDC-associated (CD11c, B220, NKR-P1A) and DC-related surface
antigens. Histogram overlays show expression of the indicated markers (solid line histograms) compared to their respective isotype controls (filled
grey histograms). All plots are representative of at least 4 independent experiments.
doi:10.1371/journal.pone.0051851.g001
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Lysis by IL-15 DCs is not due to contamination by
cytotoxic lymphocytes
IL-15 DC cultures were routinely checked for purity by
multiparameter flow cytometry in order to exclude the possibility
that cytotoxicity results were confounded by culture contamination
with cytotoxic lymphocytes. As mentioned above, IL-15 DCs
could be clearly distinguished from residual lymphocyte subsets on
the basis of their distinct FSC/SSC profile, their intense uniform
expression of CD11c and lack of CD7 expression. Both CD56+
and CD562 IL-15 DC preparations were found to contain minute
numbers of contaminating lymphocytes. The percentage of CD7+
cells within the contaminating lymphocyte cluster, which includes
NK cells and other cytotoxic lymphocytes [26], was 0.960.2% for
CD56+ IL-15 DC cultures and 1.160.3% for CD562 IL-15 DC
cultures (n = 12).
To further address the possibility that the observed lytic activity
against K562 cells might have resulted from this low-level
contamination with NK cells, we additionally performed a cyto-
toxicity assay against the U937 cell line, another known NK cell-
sensitive target cell line [25,31]. As shown in Figure S2, both
CD56+ and CD562 IL-15 DC preparations failed to affect the
viability of U937 cells, even at the high 50:1 E:T ratio used,
indicating that the presence of these few NK cell contaminants was
not a major concern in our experimental design.
IL-15 DCs contain TRAIL, express and secrete granzyme B
but lack perforin
The logical next step was to determine the mechanisms that
underlie the killing activity of IL-15 DCs. In view of the above
observation that the cytotoxic action of these cells relies primarily
Table 1. Phenotypic difference between matured CD56+ and CD562 IL-15 DCs.
DMFI % positive cells
CD562 IL-15 DCs CD56+ IL-15 DCs CD562 IL-15 DCs CD56+ IL-15 DCs
CD11c 262.6640.1 364.0651.5* 98.560.6 99.060.6*
BDCA-1/CD1c (n = 4) 19.165.3 39.769.3 60.064.4 74.564.0
CD14 (n = 6) 16.364.2 10.963.5* 51.565.8 40.565.4*
DC-SIGN/CD209 4.761.1 6.061.6 40.964.4 44.065.4
CD40 169.7621.8 227.6623.6* 97.960.9 98.960.5*
CD80 6.861.3 9.361.8* 59.764.8 65.064.8
CD86 168.4621.3 223.5628.9* 97.160.6 98.160.5*
HLA-DR 106.3612.9 107.0613.9 96.560.8 96.061.1
CCR7 7.263.1 11.163.7* 35.868.7 46.468.8*
CD83 13.863.6 19.165.4* 62.366.4 68.165.7*
Pairwise comparison of CD562 and CD56+ IL-15 DC surface phenotypes. Results are presented as mean (6 SEM) DMFI values and as mean (6 SEM) percentage of cells
staining positive for the indicated cell surface marker. Data are from 7 independent experiments, except if specified otherwise. Asterisks indicate a statistically significant
difference in cell surface marker expression between CD56+ and CD562 IL-15 DC populations (P,0.05).
doi:10.1371/journal.pone.0051851.t001
Figure 2. Allostimulatory capacity of CD56+ and CD562 IL-15 DCs in a MLR. CD56+ and CD562 IL-15 DCs were co-cultured with allogeneic,
CFSE-labeled lymphocytes at a 1:10 ratio for 5 days. CFSE-labeled cells stimulated with IL-4 DCs (1:10 stimulator/responder ratio) or PHA/IL-2 were
used as positive controls. Histograms show the degree of CFSE dilution, indicative of T cell proliferation, among gated CD3+CD4+ T cells in the
absence (filled grey histograms) and presence (solid line histograms) of the indicated stimulators. Numbers above the bracketed lines indicate the
background-subtracted percentages of proliferated (i.e. CFSElow) T cells within the CD3+CD4+ gate. Data shown are representative of three donors.
doi:10.1371/journal.pone.0051851.g002
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on the induction of apoptosis, we focused on the most common
apoptotic cell death pathways. As shown in Figure 5A, we found
no evidence for cell surface expression of the apoptotic death
receptor ligands TNF-a, FasL or TRAIL. We next performed
intracellular staining experiments to examine the possible in-
volvement of intracellular lytic molecules. In these experiments,
DCs were identified on the basis of their characteristic FSC/SSC
profile and CD11c positivity. Interestingly, both CD56+ and
CD562 IL-15 DCs contained intracellular TRAIL protein, which
was found to be expressed at a significantly higher level in the
CD56+ IL-15 DC subset (Figure 5B; DMFI for intracellular
TRAIL in CD56+ vs. CD562 IL-15 DCs: P=0.03). Furthermore,
intracellular cytokine staining revealed that both CD56+ and
CD562 IL-15 DCs expressed considerable levels of granzyme B,
albeit that the CD56+ fraction expressed significantly more
granzyme B than the CD562 DC subset (Figure 5B; DMFI for
intracellular granzyme B in CD56+ vs. CD562 IL-15 DCs:
33.0610.7 vs. 23.367.8; P=0.004). In line with this, we observed
a superior granzyme B secretory capacity of CD56+ IL-15 DCs
(1121.06353.3 pg/mL) over their CD562 counterparts
(452.36117.0 pg/mL) (Figure 5C; P=0.047). Strikingly, whereas
Figure 3. Differential ability of CD56+ and CD562 IL-15 DCs to stimulate a WT1-specific CTL clone. Mature CD56+ and CD562 IL-15 DCs
were electroporated (EP) with WT1 RNA and co-cultured with an HLA-A*0201-restricted WT1126–134-specific CTL clone. Negative controls included: T
cells cultured without DCs (T cells only), WT1 RNA-electroporated DCs cultured without T cells (DCs only), and T cells cultured with non-antigen-
loaded DCs (non/mock EP). (A) After overnight incubation, IFN-c concentrations (pg/mL) in the culture supernatants were measured by ELISA. Bars
represent mean (6 SEM) IFN-c concentrations of triplicate wells of three independent experiments (**, P= 0.003). (B) Antigenic responses were
quantified in parallel by IFN-c ELISpot. Illustrative single-well images from an IFN-c ELISpot plate of one representative experiment are shown. Values
in parentheses indicate the mean (6 SEM) number of IFN-c spot-forming cells (SFCs) of triplicate ELISpot wells.
doi:10.1371/journal.pone.0051851.g003
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intracellular levels of TRAIL and granzyme B were increased,
perforin expression was found to be absent (Figure 5B).
The cytotoxic activity of IL-15 DCs predominantly relies
on granzyme B
Based on the data above, we envisaged two putative mechan-
isms underlying the cytotoxic action of CD56+ IL-15 DCs:
TRAIL- and/or granzyme B-dependent apoptosis. To further
dissect the relative contributions of these pathways to the pro-
apoptotic effect of CD56+ IL-15 DCs on K562 cells, we performed
cytotoxicity blocking experiments using anti-TRAIL neutralizing
antibodies and concanamycin A, a selective inhibitor of vacuolar-
type H+-ATPase that prevents acidification and degranulation of
perforin/granzyme-containing cytotoxic granules. Since cytotox-
icity of CD56+ IL-15 DCs against K562 cells was most prominent
at high E:T ratios, we chose the E:T ratio of 50:1 for all further
Figure 4. Lysis of K562 cells but not of a WT1-specific CTL clone by IL-15 DCs. PKH67-labeled target cells were mixed at varying E:T ratios
with mature CD56+ and CD562 IL-15 DCs or, where indicated, with conventionally generated IL-4 DCs and then subjected to PI/Annexin-V staining
after overnight incubation. Target cell viability was defined as the percentage of PI2/Annexin-V2 cells within the PKH67+CD11c2 gate. (A) Viability
profiles of gated K562 tumor cells cultured alone (control) or with either CD562 or CD56+ IL-15 DCs at an E:T ratio of 50:1. One representative
experiment out of five is shown. Percentages of viable K562 cells are displayed in the lower left quadrants and expressed as mean (6 SEM) of 5
independent experiments. (B) Graph depicting the specific lysis of K562 tumor cells by CD56+ IL-15 DCs (solid black line,&; n=5), CD562 IL-15 DCs
(solid grey line,%; n=5) and IL-4 DCs (dashed grey line,#; n= 3) at the indicated E:T ratios. Results are expressed as mean (6 SEM) percentages of
specific lysis. Asterisks refer to a statistically significant difference in cytotoxic activity at the indicated E:T ratio between CD56+ and CD562 IL-15 DCs.
(C) Bar graphs showing the viability of a WT1126–134-specific CTL clone after overnight culture in the absence or presence of either CD56
2 (%) or
CD56+ (&) IL-15 DCs at an E:T ratio of 50:1. Data are presented as mean (6 SEM) percentages of viable T cells from three experiments.
doi:10.1371/journal.pone.0051851.g004
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Figure 5. Expression of lytic molecules by IL-15 DCs. (A) Matured CD56+ IL-15 DCs were analyzed by flow cytometry for cell surface expression
of TNF-a, FasL and TRAIL (solid line histograms). Filled grey histograms represent isotype controls. Data are from one experiment representative of
three. (B) Both CD56+ (solid line) and CD562 (dashed line) IL-15 DCs were stained for intracellular expression of TRAIL, granzyme B and perforin. Filled
grey histograms represent isotype controls. One representative experiment out of 6 (for TRAIL) and 9 (for granzyme B and perforin) is shown. (C)
Supernatants from overnight washout cultures of CD56+ (&) and CD562 (%) IL-15 DCs were analyzed for granzyme B release by ELISA. Bars represent
mean (6 SEM) granzyme B concentations (pg/mL) from 7 experiments.*, P,0.05.
doi:10.1371/journal.pone.0051851.g005
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blocking experiments. As shown in Figure 6, neutralization of
TRAIL activity resulted in a net decrease in cytotoxicity by
4.660.7% as compared to isotype control, corresponding to
a 22.562.8% inhibition (Figure 6; P=0.03). Upon incubation
with concanamycin A, cytotoxicity of CD56+ IL-15 DCs against
K562 was reduced from 24.266.3% (control medium) to
6.461.1%, corresponding to a 62.966.1% inhibition (Figure 6,
P=0.001). Taken together, these results confirmed that granzyme
B and, to a small extent, TRAIL participated in the observed
cytotoxicity of IL-15 DCs.
Discussion
Dendritic cells, the quintessential antigen-presenting cells of the
human immune system, have attracted much interest for active,
specific immunotherapy of cancer over the years [32]. Despite
some clinical successes, there is a general consensus that DC-based
anti-tumor immunotherapy has not yet fulfilled its full therapeutic
potential and that there remains considerable room for improve-
ment, especially when it comes to optimizing the immunostimu-
latory activity of the DCs used for clinical application [32,33]. Due
to their potent immunostimulatory properties, monocyte-derived
DCs generated in the presence of GM-CSF and IL-15 (IL-15 DCs)
have been advocated as promising new vehicles for DC-based
immunotherapy [17,21–23]. In this study, we reveal for the first
time that IL-15 DCs, in addition to a robust capacity for tumor
antigen presentation, possess tumor cell killing potential. Our
findings thus establish a previously unrecognized ‘killer DC’
function for IL-15 DCs, providing further support to their
application in DC-based cancer immunotherapy protocols.
Although a subset of IL-15 DCs expresses the archetypal NK
cell marker CD56 [34], we found no evidence for a further
phenotypic overlap between IL-15 DCs and NK cells, nor could
these cells be identified as the human homologue of murine
NKDCs [4–9]. Our phenotypic data unequivocally establish that
IL-15 DCs are genuine monocyte-derived DCs despite the rather
unconventional expression of CD56. Perhaps the most compelling
evidence for this comes from our cell sorting experiment in which
CD14+ monocytes were flow sorted to ultra-high purity and then
subjected to IL-15 DC differentiation. In this experiment, we
showed that CD56+ IL-15 DCs can also be differentiated from
a virtually pure, FACS-sorted CD14++CD162 monocyte starting
population, thus confirming that these cells are truly monocyte-
derived and not related to NK cells. In addition, CD56+ IL-15
DCs fall within the flow cytometric scatter gate of DCs, but not of
lymphocytes. The co-expression of the myeloid DC lineage
markers BDCA-1 and CD11c along with the absence of CD7
expression, which allows their accurate discrimination from NK
cells [26,35], lends further support to the notion that IL-15 DCs
are unrelated to NK cells in spite of their partial positivity for
CD56.
To corroborate these phenotypic data and to confirm that IL-15
DCs also functionally qualify as DCs, we performed an allo-MLR
as well as an antigen presentation assay. Both CD56+ and CD56–
IL-15 DCs are able to stimulate allogeneic T cell proliferation,
thereby fulfilling one of the basic functional criteria for being
qualified as DCs [29]. Furthermore, in this study, we also show
that IL-15 DCs, as would be expected from DCs, are capable of
processing and presenting the WT1 tumor antigen [30] to CD8+ T
cells. Together with previous observations from our group and
others [17,21,22], these data confirm that IL-15 DCs are
‘‘authentic’’ myeloid DCs not only from the phenotypic but also
from the functional point of view. Strikingly, in the WT1 antigen
presentation assay, CD56+ IL-15 DCs were found to have
a superior antigen-presenting capacity over their CD56– counter-
parts. Both fractions had comparable expression of the WT1
protein following electroporation (data not shown), suggesting that
CD56+ DCs have a higher intrinsic ability to process and present
endogenously synthesized antigen to T cells. Although the precise
functional role of CD56 on DCs remains to be elucidated, the
above data suggest that the expression of CD56 on DCs is linked
with superior immunostimulatory activity. This mirrors the
situation in NK cells and CD56-expressing T cells where CD56
expression and antigen density correlate with activation status and
enhanced immune function [1,36–43]. Further support for this
statement comes from the phenotypic data presented in Table 1,
which show that CD56+ IL-15 DCs are in a more differentiated
and activated modus as compared to their CD56– counterparts.
The observation that CD56+ IL-15 DCs, in addition to being
potent allostimulatory and antigen-presenting cells, are endowed
with a cytotoxic capacity is a novel finding that adds to the
growing body of evidence that DCs can adopt an ‘‘unconvention-
al’’ cytotoxic effector function and act as killer cells (reviewed in
[10–12,14]). Among the stimuli capable of triggering such ‘killer
DC’ function are type I and II IFNs [44–49], TLR ligands
[13,48,50–53] and, as shown here and in another recent study, IL-
15 [54]. The fact that IL-15, a known growth factor for NK cells
[34], was used in this study for DC differentiation as well as the
fact that IL-15 DCs were found to be cytotoxic against the NK
Figure 6. Inhibition of CD56+ IL-15 DC-mediated cytotoxicity
by neutralizing anti-TRAIL mAbs and concanamycin A. Matured
CD56+ IL-15 DCs were co-cultured with PKH67-labeled K562 target cells
at an E:T ratio of 50:1 in the presence of either anti-TRAIL blocking mAb
(left) or the granule exocytosis inhibitor concanamycin A (right). Parallel
experiments were performed using TRAIL isotype-matched control mAb
and medium control devoid of concanamycin A, respectively. Lysis of
target cells was determined after overnight incubation using a flow
cytometry-based cytotoxicity assay, as described above. Results are
expressed as mean (6 SEM) percentages of specific target cell lysis.
Data are from 5 (for TRAIL) and 10 (for concanamycin) independent
experiments. *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0051851.g006
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prototype target K562 [25], prompted us to perform rigorous
culture purity assessments in order to exclude the possibility that
the observed cytotoxic effects were due to the presence of
contaminating NK cells. Based on the model proposed by Stary
et al. [53], at least 10% of NK cell contaminants would have been
needed to account for the cytotoxic activity reported in the present
study. The trace contamination (,1%) of IL-15 DC cultures by
lymphocytes was thus far too low to account for the observed
cytotoxic effects and was therefore considered negligible [53]. This
was also further supported by the finding that neither CD562 nor
CD56+ IL-15 DC preparations had cytotoxic activity against the
U937 cell line, another well-recognized NK-sensitive target
[25,31].
The lack of cytotoxicity against U937 identifies a second point
of difference between IL-15 DCs and NK cells, in addition to the
finding that these cells do not share any phenotypic resemblance
except for CD56 surface expression. Indeed, as discussed above,
IL-15 DCs do not bear any other NK cell-associated surface
markers, such as NKG2D or NCRs. The mechanism underlying
the ability of NK cells to induce U937 cell death has been recently
identified as being NCR-mediated [31], likely explaining the
absent cytotoxic activity of IL-15 DCs against U937 cells. Another
striking dissimilarity between IL-15 DCs and NK cells that merits
further discussion is their differential pattern of cytotoxicity against
the K562 cell line. While NK cells are strong and rapid inducers of
K562 cell death, the anti-K562 cytotoxic activity of IL-15 DCs
occurs only in the higher E:T range and with much slower
dynamics. Interestingly, this intrinsically lower lytic potential has
also been reported in other ‘killer DC’ studies and thus appears to
be a common feature that distinguishes killer DCs from ‘‘classical’’
cytotoxic effector cells such as NK cells [46,52,53,55–57]. The
observation that IL-15 DCs display a distinct lytic profile further
supports our view that these cells, despite the non-conforming
expression of CD56, should be regarded as bona fide DCs endowed
will killing potential and not as NK cells with antigen-presenting
function [2].
An important finding from this study is that IL-15 killer DCs do
not induce cell death of tumor antigen-specific T cells, suggesting
that their cytotoxic action is tumor-selective. This is especially
noteworthy in view of recent data from Luckey et al., who showed
that murine killer DCs are capable of eliminating allergen-specific
T cells through a TNF-a-dependent mechanism and, as such, of
preventing mice from developing allergic contact dermatitis [58].
In line with this, murine CD8+ DCs have been previously shown
to be capable of inducing T cell apoptosis through the Fas/FasL
pathway [59]. DC-mediated killing of T cells has also been
demonstrated in the context of HIV infection [11,60]. Evidently,
the possibility of T cell killing would represent a major obstacle to
the exploitation of killer DCs for cancer immunotherapy. Our
data, however, indicate that T cell-directed cytotoxicity is not
a general feature of killer DCs. This is consistent with the
emerging view that killer DCs are a heterogeneous population,
containing subsets that are preferentially tumoricidal as well as
others that appear to be more biased toward a tolerogenic profile
(e.g. through their ability for T cell killing) [10].
This heterogeneity also applies to the different cytotoxic effector
mechanisms that can be used by killer DCs. FasL and TNF-a,
previously described as key components of the lytic armamentar-
ium of killer DCs [10,11,45,59], are not found to be expressed on
the IL-15 DC surface, thus arguing against their possible
involvement in IL-15 DC-mediated killing. Although they lack
membrane expression of TRAIL, IL-15 DCs – in particular the
CD56+ fraction – harbor an internal pool of TRAIL molecules.
Nevertheless, TRAIL neutralization resulted only in a marginal
reduction of the lytic activity of CD56+ IL-15 DCs against K562
cells, indicating that TRAIL is not a major contributor to the
cytotoxic action of these DCs. This is in contrast to several other
studies that implied an important role for this death receptor
ligand in DC-mediated cytotoxicity [44,46,48,53]. Our results
point to granzyme B-induced apoptosis as the main cell death
pathway used by IL-15 DCs. The presence of intracellular
granzyme B deposits in IL-15 DCs was ascertained by direct
gating on the DC population on the basis of a combination of
scatter profile and CD11c positivity. The functional importance of
this expression was further supported by the capacity of IL-15 DCs
to release granzyme B extracellularly and ultimately confirmed by
the profound reduction of their cytotoxic activity using con-
canamycin A, which is commonly used to inhibit the perforin/
granzyme B cytotoxic pathway [13,53]. Intriguingly, we were
unable to reveal expression of perforin in IL-15 DCs. This
observation is in contrast to the study of Stary et al. in which
TLR7/8-stimulated blood myeloid DCs were found to express
both perforin and granzyme B [53], but is congruent with a recent
report showing that mouse plasmacytoid DCs can kill in
a granzyme B-dependent, perforin-independent fashion [13].
Although puzzling at first sight, the discordant expression of
perforin and granzyme B apparently does not preclude IL-15 DCs
from inducing K562 cell death. This complements the notion that
granzyme B-induced apoptosis can still occur in the absence of
perforin, although not with the same efficiency or rapidity [61–
63]. The lack of perforin expression in IL-15 DCs may thus
provide a plausible explanation for their differential lytic profile as
compared to ‘‘classical’’ cytotoxic effector cells such as NK cells,
which typically contain high levels of both perforin and granzyme
B enabling them to induce rapid target cell death [63,64].
In conclusion, we show here that IL-15 can drive the functional
repertoire of human monocyte-derived DCs toward a killer DC
profile. This study showcases the considerable potential for
phenotypic and functional flexibility of human DCs and provides
new converging evidence of the possibility that DCs can adopt
a cytotoxic effector function. The observation that IL-15 DCs, in
addition to being potent tumor antigen-presenting cells, are
endowed with tumoricidal potential provides further strong
support to the implementation of IL-15 DCs in DC-based anti-
tumor immunotherapy strategies and to the use of IL-15 as an
immunostimulatory adjunct in cancer therapy.
Supporting Information
Figure S1 Kinetics of CD56 expression on IL-15 DCs.
FACS-purified (.99.9% purity) CD14+ monocytes were cultured
for 7 days with GM-CSF and IL-15 and analyzed by flow
cytometry at the time points indicated for co-expression of
CD11c/CD56 (right panels). Samples were stained in parallel
with CD11c and an isotype-matched control mAb for CD56 to
allow proper gate setting (left panels). Data shown are from a single
donor and are representative of two separate experiments.
(TIF)
Figure S2 Lack of cytotoxicity by CD56+ and CD562 IL-
15 DCs against the U937 target cell line. Residual viability
of PKH67-labeled U937 cells after overnight incubation in the
absence or presence of either CD562 (%) or CD56+ (&) mature
IL-15 DCs at an E:T ratio of 50:1. Viability was determined by
flow cytometric quantitation of the percentage of PI2/Annexin-
V2 – cells within the PKH67+CD11c2 gate. Bars represent mean
(6 SEM) percentages of viable cells from three independent
experiments.
(TIF)
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